Do analysts recommend RDY or RCUS?

Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 24.64%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58

Does the media favor SMMT or RCUS?

In the previous week, Summit Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Summit Therapeutics and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Summit Therapeutics' score of 0.84 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ARWR or RCUS?

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Arrowhead Pharmaceuticals' score of 1.04 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RCUS or NUVL?

In the previous week, Nuvalent had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 3 mentions for Nuvalent and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Nuvalent's score of 1.49 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRYS or RCUS?

In the previous week, Krystal Biotech had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 5 mentions for Krystal Biotech and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Krystal Biotech's score of 1.10 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Arcus Biosciences (RCUS) Competitors

$28.16 +0.93 (+3.42%)

Closing price 06/23/2026 03:58 PM Eastern

Extended Trading

$27.98 -0.18 (-0.65%)

As of 06/23/2026 07:15 PM Eastern

Compare

RCUS vs. RDY, SMMT, ARWR, NUVL, and KRYS

Should you buy Arcus Biosciences stock or one of its competitors? MarketBeat compares Arcus Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcus Biosciences include Dr. Reddy's Laboratories (RDY), Summit Therapeutics (SMMT), Arrowhead Pharmaceuticals (ARWR), Nuvalent (NUVL), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Arcus Biosciences had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 1 mentions for Arcus Biosciences and 0 mentions for Dr. Reddy's Laboratories. Arcus Biosciences' average media sentiment score of 1.71 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
Arcus Biosciences	Very Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcus Biosciences' net margin of -156.36%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Dr. Reddy's Laboratories has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.33	$456M	$0.58	24.62
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 24.64%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Arcus Biosciences beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, Summit Therapeutics had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 2 mentions for Summit Therapeutics and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Summit Therapeutics' score of 0.84 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summit Therapeutics presently has a consensus target price of $27.23, suggesting a potential upside of 91.05%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 24.64%. Given Summit Therapeutics' higher possible upside, equities analysts clearly believe Summit Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Arcus Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A

Summary

Arcus Biosciences beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Arcus Biosciences' net margin of -156.36%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Arrowhead Pharmaceuticals currently has a consensus price target of $86.36, indicating a potential upside of 8.09%. Arcus Biosciences has a consensus price target of $35.10, indicating a potential upside of 24.64%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Arrowhead Pharmaceuticals' score of 1.04 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.57	-$1.63M	-$2.15	N/A
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A

Summary

Arrowhead Pharmaceuticals beats Arcus Biosciences on 10 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Nuvalent?

Arcus Biosciences (NYSE:RCUS) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arcus Biosciences currently has a consensus price target of $35.10, suggesting a potential upside of 24.64%. Nuvalent has a consensus price target of $131.15, suggesting a potential upside of 6.25%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Arcus Biosciences is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Nuvalent had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 3 mentions for Nuvalent and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Nuvalent's score of 1.49 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Arcus Biosciences has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Nuvalent's return on equity of -40.11% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Nuvalent	N/A	-40.11%	-35.43%

Summary

Arcus Biosciences beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Krystal Biotech had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 5 mentions for Krystal Biotech and 1 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.71 beat Krystal Biotech's score of 1.10 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Krystal Biotech currently has a consensus target price of $340.56, indicating a potential upside of 0.10%. Arcus Biosciences has a consensus target price of $35.10, indicating a potential upside of 24.64%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Krystal Biotech has a net margin of 53.92% compared to Arcus Biosciences' net margin of -156.36%. Krystal Biotech's return on equity of 19.25% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Krystal Biotech beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$3.42B	$3.45B	$6.44B	$23.25B
Dividend Yield	N/A	2.30%	2.69%	4.07%
P/E Ratio	-8.86	19.75	24.66	31.08
Price / Sales	14.34	332.72	528.64	16.29
Price / Cash	N/A	128.56	44.82	24.45
Price / Book	4.82	8.29	10.79	4.64
Net Income	-$353M	$23.85M	$3.56B	$1.07B
7 Day Performance	16.59%	2.87%	1.01%	0.15%
1 Month Performance	19.95%	2.19%	0.43%	0.18%
1 Year Performance	221.28%	55.48%	29.71%	23.21%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	3.3554 of 5 stars	$28.16 +3.4%	$35.10 +24.6%	+225.7%	$3.42B	$247M	N/A	500
RDY Dr. Reddy's Laboratories	1.6224 of 5 stars	$13.33 +0.2%	N/A	-6.7%	$11.10B	$3.58B	22.99	27,527
SMMT Summit Therapeutics	3.8191 of 5 stars	$14.13 +0.9%	$27.23 +92.7%	-30.1%	$10.87B	N/A	N/A	110	Gap Down
ARWR Arrowhead Pharmaceuticals	2.0622 of 5 stars	$77.15 +3.5%	$87.80 +13.8%	+415.2%	$10.50B	$829.45M	N/A	400	Positive News Gap Down
NUVL Nuvalent	1.8853 of 5 stars	$123.35 +0.1%	$131.15 +6.3%	+62.5%	$9.74B	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. RDY, SMMT, ARWR, NUVL, and KRYS

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does Arcus Biosciences compare to Nuvalent?

Summary

How does Arcus Biosciences compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. RDY, SMMT, ARWR, NUVL, and KRYS

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Do institutionals and insiders hold more shares of RDY or RCUS?

Does the media prefer RDY or RCUS?

Is RDY or RCUS more profitable?

Which has preferable valuation & earnings, RDY or RCUS?

Which has more volatility and risk, RDY or RCUS?

Do analysts recommend RDY or RCUS?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Which has more volatility and risk, SMMT or RCUS?

Does the media favor SMMT or RCUS?

Do analysts recommend SMMT or RCUS?

Do institutionals and insiders hold more shares of SMMT or RCUS?

Is SMMT or RCUS more profitable?

Which has higher earnings & valuation, SMMT or RCUS?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Is ARWR or RCUS more profitable?

Do analysts rate ARWR or RCUS?

Do institutionals and insiders believe in ARWR or RCUS?

Does the media favor ARWR or RCUS?

Which has more risk & volatility, ARWR or RCUS?

Which has stronger valuation and earnings, ARWR or RCUS?

Summary

How does Arcus Biosciences compare to Nuvalent?

Do institutionals and insiders hold more shares of RCUS or NUVL?

Do analysts prefer RCUS or NUVL?

Does the media refer more to RCUS or NUVL?

Which has more risk and volatility, RCUS or NUVL?

Which has stronger earnings and valuation, RCUS or NUVL?

Is RCUS or NUVL more profitable?

Summary

How does Arcus Biosciences compare to Krystal Biotech?

Does the media refer more to KRYS or RCUS?

Do institutionals and insiders have more ownership in KRYS or RCUS?

Which has preferable valuation and earnings, KRYS or RCUS?

Which has more volatility & risk, KRYS or RCUS?

Do analysts rate KRYS or RCUS?

Is KRYS or RCUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools